It governs Therapeutics
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Refractory Lupus Nephritis
Myasthaenia Gravis
Stiff Person Syndrome
Rheumatoid Arthritis (RA)
Multiple Sclerosis
Dermatomyositis
Systemic Sclerosis (SSc)
KYV-101
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 70 participants |
| Official Title : | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101 |
| Actual Study Start Date : | 2025-11-24 |
| Estimated Primary Completion Date : | 2041-01 |
| Estimated Study Completion Date : | 2041-01 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
University of Colorado, Denver
Denver, Colorado, United States, 80045